KAS
FOLD

Kemnay Advisory Services’s Amicus Therapeutics FOLD Stock Holding History

Kemnay Advisory Services’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,767
Closed -$125K – 1235
2025
Q4 		$125K Buy
+8,767
New +$86.1K 0.02% 107

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Kemnay Advisory Services's FOLD Position: Q1 2026 in Review

Kemnay Advisory Services sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 8,767 shares — an estimated $125K sold.

Kemnay Advisory Services first reported a position in FOLD in Q4 2025 and held it in 1 quarter. The position peaked at $125K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Kemnay Advisory Services reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kemnay Advisory Services sold 8,767 Amicus Therapeutics shares in Q1 2026, an estimated $125K.
  • Kemnay Advisory Services first reported a position in Amicus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Kemnay Advisory Services's Amicus Therapeutics position peaked at $125K in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.